New Immunotherapies for Metastatic Cancer


Despite considerable progress over the past several decades in treating various early stage cancers, prognosis for patients with late stage metastatic disease is still quite poor.

We are working with the developers of several new drugs and devices for immunologic treatment of advanced metastatic cancers. These treatments have shown promising results, in some cases significantly exceeding the standard of care. None of these treatments we are focusing on are currently available in the U.S., which is why we are organizing clinical trials under the FDA’s Expanded Access guidelines.